Neurogene (NGNE) Operating Income (2017 - 2026)

Neurogene has reported Operating Income for 10 years, with the latest figure at -$33.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 28.67% year-over-year to -$33.3 million; the trailing twelve-month figure through Mar 2026 stood at -$110.8 million (down 23.41% YoY), and the FY2025 full-year result was -$103.3 million, down 25.09% from the prior year.
• Operating Income for Q1 2026 stood at -$33.3 million, down from -$27.5 million in the prior quarter.
• The five-year high for Operating Income was -$11.7 million in Q4 2022, with the low at -$33.3 million in Q1 2026.
• Historically, Operating Income has averaged -$19.5 million across 5 years, with a median of -$18.8 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Income climbed 23.09% — and 2024, when it tumbled 59.84%.
• Neurogene's Operating Income stood at -$11.7 million in 2022, then dropped by 26.24% to -$14.7 million in 2023, then sank by 46.01% to -$21.5 million in 2024, then declined by 27.97% to -$27.5 million in 2025, then dropped by 21.14% to -$33.3 million in 2026.
• The last three Operating Income figures came in at -$33.3 million (Q1 2026), -$27.5 million (Q4 2025), and -$23.8 million (Q3 2025), per Business Quant data.